Pain Therapeutics (PTIE) Shares are Down -63.37%

Pain Therapeutics (PTIE) : During the past 4 weeks, traders have been relatively bearish on Pain Therapeutics (PTIE), hence the stock is down -55.71% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -63.43% relative to the S&P 500. The 4-week change in the price of the stock is -55.95% and the stock has fallen -63.37% in the past 1 week.

The stock has recorded a 20-day Moving Average of 55.41% and the 50-Day Moving Average is 58.87%.The 200 Day SMA reached 53.52%

Pain

Pain Therapeutics (NASDAQ:PTIE): The stock opened in the green at $1.03 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $1.07 and a low of $0.989 for the day. The stock did not find buyers even at the lows and closed at $0.9999 recording a loss of -1.00%. 2,228,129 shares exchanged hands during the trading day. The stock had closed at $0.9999 in the previous days trading.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops drugs. The Companys lead drug candidate, REMOXY, is an extended-release oral formulation of oxycodone for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. REMOXY is a controlled-release oral capsule form of oxycodone in a viscous liquid formulation matrix that includes excipients. REMOXYs capsule dosage form provides therapeutic drug levels of oxycodone on a twice-daily dosing schedule, while resisting the increases in plasma levels of oxycodone associated with certain common methods of abuse and misuse. The Companys drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational New Drug-stage of development.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.